BOSTON, July 31 /PRNewswire-FirstCall/ -- FluoroPharma Inc., a company developing breakthrough cardiovascular PET molecular imaging diagnostics, announced today that Dr. Todd R. Nelson joined FluoroPharma's Board of Directors as an Independent Director, and Dr. Elazer Edelman joined FluoroPharma's Scientific Advisory Board.
Dr. Todd R. Nelson is currently Vice President Corporate Development and Strategy at Invitrogen Corporation and previously was Managing Director and Head, Global Life Sciences Corporate Strategy and Research at the Royal Bank of Canada Capital Markets (formerly Dain Rauscher Wessels) and was First Vice President, Corporate Research and Economics at Merrill Lynch. Throughout his career, Dr. Nelson has been involved with numerous mergers & acquisitions, IPOs, licensing agreements, and the formation of strategic alliances within the life sciences and medical technology sectors.
"I am honored to join FluoroPharma as a member of the Board of Directors and to have an opportunity to work with so many of the leaders in the field of cardiovascular medicine and molecular imaging. FluoroPharma's products represent a clear potential advantage over other products on the market," said Dr. Nelson.
Dr. Elazer Edelman, Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology at MIT, Professor of Medicine at Harvard Medical School, and a coronary care unit cardiologist at the Brigham and Women's Hospital in Boston, joined FluoroPharma's Scientific Advisory Board. Dr. Edelman currently directs the Harvard-MIT Biomedical Engineering Center (BMEC) and pioneered significant findings in vascular biology.
"We share the vision of expanding PET molecular imaging technologies," said Dr. David Elmaleh, FluoroPharma's founder and Chairman of the Board. "The combination of Todd's extraordinary track record in finance, corporate development and operations, and Elazer's experience in advancing science and new concepts in cardiology, further strengthens FluoroPharma's foundation."
"FluoroPharma achieved several important milestones this year," said Dr. Ljiljana Kundakovic, President of FluoroPharma. "We are looking forward to working with Dr. Nelson and Dr. Edelman towards advancing our cardiovascular PET products into the next stage of development."
About FluoroPharma
FluoroPharma is a molecular imaging company engaged in the discovery and development of proprietary products for the PET market. FluoroPharma is advancing three proprietary products for assessment of acute and chronic forms of coronary disease. FluoroPharma's lead product CardioPET is in Phase I clinical trials. Two other cardiovascular molecular imaging products, BFPET, a novel blood flow PET imaging agent, and VasoPET, the first PET molecular imaging agent to allow for detection of vulnerable atherosclerotic plaque, are in preclinical development. These agents have been designed to rapidly target either the myocardial cells within the heart or vulnerable plaques within the coronary arteries. http://www.fluoropharma.com.
QuantRx Biomedical Corporation is FluoroPharma's majority investor. FluoroPharma's founder is Dr. David Elmaleh, a leader in molecular imaging, with support from PureTech Ventures.
About QuantRx
QuantRx Biomedical Corporation is a leading biomedical research, development and manufacturing company with corporate offices in Doylestown, Pennsylvania. The firm specializes in creating innovative medical technology platforms and products for diagnosis and treatment of a wide range of medical needs. http://www.quantrx.com
About PureTech Ventures
PureTech is a life science venture firm specializing in translation of academic innovation. http://www.puretechventures.com
This release may contain forward-looking statements within the meaning of federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict, including; the company's need for additional funds, the company's dependence on a limited number of imaging compounds, the early state of the products the company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the company's ability to avoid infringement of the patent rights of others, the company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. FluoroPharma does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.
FluoroPharma Inc.CONTACT: Ljiljana Kundakovic of FluoroPharma Inc., +1-617-482-2333, ext.16
